Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
EIR
•Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.•April 12, 2019

Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc. – FDA EIR, Apr 12, 2019

Record Details

An FDA inspection was conducted at UPM Pharmaceuticals, Inc. in Bristol, TN, from April 8 to April 12, 2019, under the regulatory framework of Current Good Manufacturing Practices (21 CFR 211). The inspection identified significant deficiencies in the company's manufacturing and quality control systems. Main violations included the failure to adequately manage environmental monitoring system alarms, leading to numerous unaddressed temperature, humidity, and pressure excursions. This resulted in the prolonged storage of capsules under conditions exceeding supplier recommendations, with these potentially compromised materials subsequently used in commercial and non-commercial products. The firm also exhibited inadequate documentation practices, evidenced by untracked production records, and failed to thoroughly investigate out-of-specification results, closing one investigation without determining a root cause or implementing corrective actions. Management acknowledged the findings on the FDA Form 483 and committed to retraining staff on alarm response, revising alarm acknowledgment responsibilities, conducting temperature mapping, and improving complaint and investigation documentation. They were informed of the requirement to formally respond to the FDA 483 observations within fifteen days.

Company
Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
Inspection date
April 12, 2019
Product type
drugs
Office
New Orleans District Office
People
  • Patrick Hatem (company_representative)
  • James E. Gregory (recipient)
  • Herschel Blessings (company_representative)
  • Tracy Washington Wells (investigator)
  • Elisabeth Landing (company_representative)
View Company Profile

ID · 6e0f2f2a-756f-4a43-9f47-13be030e7213

Violation Codes5
21 CFR 211.100(a)21 CFR 211.80(b)21 CFR 211.19221 CFR 820.5021 CFR 211.125(d)

Full citation text and observation details available on the Dashboard.

Other documents for Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
  • 483 - 2024-09-20September 20, 2024
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gregory Pharmaceutical Holdings Inc. dba UPM Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.